Since the first FDA approval for weight loss, GLP-1 receptor agonists are in the news as new blockbuster drugs.

As of today, neither Novo Nordisk's Ozempic / Wegovy (Semaglutid), nor Eli Lilly's Mounjaro / Tirzepatid are projected to generate more sales than Merck's Keytruda (Pembrolizumab, a checkpoint inhibitor used in tumor therapy).

Will the newly approved GLP-1 agonists live up to the hype and sell even better than expected, becoming the new bestselling drugs on the global market?

This market will resolve YES if a GLP-1 agonist is the best-selling drug in 2023 (new sales) per reliable company or media reports.